Ramm Pharma (TSE:RAMM) has released an update.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
RAMM Pharma Corp. has recently concluded a trial concerning a multimillion-dollar litigation with former CEO Sergio Martines and NATURALE SCIENCE INC, with the judge’s decision pending. The dispute involves claims and counterclaims related to contractual breaches, share purchase obligations, and fraudulent misrepresentation, with potential financial repercussions for the company’s future statements. Amidst this legal battle, RAMM continues to operate as a leader in cannabinoid pharmaceuticals, with a strong presence in Europe and a portfolio of approved products and facilities.
For further insights into TSE:RAMM stock, check out TipRanks’ Stock Analysis page.